We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Invitrogen and RXi Pharmaceuticals Collaborate to Enhance RNAi Technologies for Therapeutic Applications
News

Invitrogen and RXi Pharmaceuticals Collaborate to Enhance RNAi Technologies for Therapeutic Applications

Invitrogen and RXi Pharmaceuticals Collaborate to Enhance RNAi Technologies for Therapeutic Applications
News

Invitrogen and RXi Pharmaceuticals Collaborate to Enhance RNAi Technologies for Therapeutic Applications

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Invitrogen and RXi Pharmaceuticals Collaborate to Enhance RNAi Technologies for Therapeutic Applications"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Invitrogen Corporation and RXi Pharmaceuticals Corporation have entered into an agreement whereby RXi will exclusively license second generation RNA interference (RNAi) technology from Invitrogen for designated target genes in all human therapeutic categories.

Invitrogen’s patent applications that are part of this agreement cover Stealth™ and other proprietary technologies related to enhanced configurations of chemically modified double-stranded RNA. Terms of the agreement were not disclosed.

“Licensing this broad technology from Invitrogen is part of our strategy to continually enhance our proprietary rxRNA™ compounds for therapeutic applications,” said Dr. Tod Woolf, President and Chief Executive Officer of RXi.

“Currently Invitrogen Stealth™ RNAi synthetic duplexes are widely used for RNAi research across both in vitro and in vivo applications due to their specificity, efficacy and stability,” said Amy Butler, Invitrogen vice president of gene expression profiling.

“We see the use of our Stealth™ RNAi technology in therapeutics as a natural next step in Invitrogen’s efforts to be at the cutting edge of in vivo gene regulation.”

Advertisement